4D pharma (DDDD) News Today → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free DDDD Stock Alerts GBX 16.66 0.00 (0.00%) (As of 11/8/2022) Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadline4D Molecular Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)markets.businessinsider.com - March 1 at 9:52 AMWhat 4 Analyst Ratings Have To Say About 4D Molecular Therapeuticsmarkets.businessinsider.com - February 7 at 8:36 AM4D Molecular Therapeutics up 3%, prices $300M equitymsn.com - February 7 at 8:36 AM4D Molecular Shares Hit 52-Week High After 4D-150 Eye Treatment Trialmarketwatch.com - February 5 at 4:31 PMHow to Trade a Surging 4D Molecular Therapeuticsrealmoney.thestreet.com - February 5 at 4:31 PMAnalysts Are Bullish on Top Healthcare Stocks: 4D Molecular Therapeutics (FDMT), Boston Scientific (BSX)markets.businessinsider.com - February 5 at 11:31 AMAnalysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Valeo Pharma (OtherVPHIF) and AbbVie (ABBV)markets.businessinsider.com - February 5 at 11:31 AMIndian pharma firm Dr Reddy's beats Q3 profit view on strong US, European businessesnews.yahoo.com - January 30 at 12:27 PMAnalysts Offer Insights on Healthcare Companies: Merus (MRUS), 4D Molecular Therapeutics (FDMT) and Inari Medical (NARI)markets.businessinsider.com - November 27 at 9:28 PMAnalysts Conflicted on These Healthcare Names: Xenon (XENE), Adverum Biotechnologies (ADVM) and 4D Molecular Therapeutics (FDMT)markets.businessinsider.com - November 11 at 10:23 AMPositive Clinical Trial Results and Future Prospects Reinforce Buy Rating for 4D Molecular Therapeutics: An Analysis by Geulah Livshitsmarkets.businessinsider.com - November 2 at 1:14 PMBMO Capital Sticks to Their Buy Rating for 4D Molecular Therapeutics (FDMT)markets.businessinsider.com - July 11 at 8:20 AM4D Molecular Poised For Success: FDA Discussion And Solid Position In Competitive Genetic Medicine Space, Says Analystmsn.com - July 5 at 3:41 PM4D Molecular Down 25% After Wet AMD Drug Updatemarketwatch.com - April 28 at 2:59 PMWhat's Going On With 4D Molecular Therapeutics Stock Todaymarkets.businessinsider.com - April 27 at 2:59 PMMicrobiome Therapeutics Market Current Trends, Segmentation, Key Players and Analysis Till 2035marketwatch.com - March 24 at 7:10 PMPharmacy Management System Market Scenario 2023 to 2028: New Developments, Economic Situation and Growth Projectionmarketwatch.com - February 14 at 8:13 AMHuman Microbiome Market Report (2022 to 2030) – Obiome, 4D Pharma, Vedanta Biosciences, Second Genome, Ferring Pharmaceuticalsfinance.yahoo.com - January 20 at 8:50 PM4D Pharma rescue by Armistice to face votethetimes.co.uk - December 30 at 11:26 PM4D pharma plc (DDDD.L)finance.yahoo.com - October 5 at 11:53 PMThe past year for 4D Molecular Therapeutics (NASDAQ:FDMT) investors has not been profitablenasdaq.com - September 26 at 2:32 PM4D pharma plc (“4D pharma”) Receives Notice of Delisting From Nasdaqapnews.com - June 30 at 7:22 AMWoodford stock pick 4D Pharma collapsesthetimes.co.uk - June 25 at 10:11 PMUpdate on Suspension of Tradingfinance.yahoo.com - June 24 at 5:09 PM4D Pharma outlines phase II plans for promising cancer drug candidateproactiveinvestors.com.au - May 27 at 3:46 AMHere’s why the 4D Pharma (LON:DDDD) share price is surging todayfool.co.uk - May 17 at 8:39 AM4D pharma Presents Late Breaking Abstract from Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma at the American Thoracic Society (ATS) 2022 International Conferencefinance.yahoo.com - May 17 at 8:39 AM4D pharma conference poster underlines safety and potential efficacy of asthma drug candidateproactiveinvestors.com - May 17 at 3:38 AMSMALL CAP MOVERS: 4D Pharma jumps; Diurnal divesmsn.com - March 25 at 5:14 PMSMALL CAP MOVERS: 4D Pharma jumps after positive results from cancer drug trial ; hormone firm Diurnal dives on need of further fundingmsn.com - March 25 at 5:14 PM4d pharma 'another stepping stone' for 4D Pharma after company hitting primary efficacy targetproactiveinvestors.com - March 25 at 5:14 PM4D Pharma PLC soars after meeting endpoint earlyproactiveinvestors.com - March 23 at 5:00 PM4D Pharma soars after meeting endpoint earlyproactiveinvestors.com - March 23 at 5:00 PMMidday Stock Movers: GameStop, 4D Pharma Rise; Adobe, Vicor Slidefinance.yahoo.com - March 23 at 5:00 PM4D Pharma Shares Soar On MRx0518/Keytruda Combo Trial Data In Renal Cell Carcinomafinance.yahoo.com - March 23 at 5:00 PM4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinomafinance.yahoo.com - March 23 at 11:59 AM4D pharma sees early success as phase I/II cancer trial hits its efficacy target earlyproactiveinvestors.com - March 23 at 6:58 AM4D pharma jumps as early success as phase I/II cancer trial hits its efficacy target earlyproactiveinvestors.com.au - March 23 at 6:58 AM4D pharma jumps on early success as phase I/II cancer trial hits its efficacy target earlyproactiveinvestors.com - March 23 at 6:58 AM4D pharma prepares the ground for potential US fundraiserproactiveinvestors.com - March 9 at 7:57 AM4D pharma to Participate at the Chardan Metagenomics and Microbiome Medicines Summitfinance.yahoo.com - February 23 at 7:13 AM4D pharma receives US regulatory green light for phase I trial of Parkinson's disease candidatesproactiveinvestors.com - February 22 at 6:44 AM4D pharma receives US regulatory green light for phase I trial of its Parkinson's disease candidatesproactiveinvestors.com - February 22 at 6:44 AM4D Pharma restates first-half earnings due to accounting changefinance.yahoo.com - February 21 at 3:36 AMHow Much Of 4D pharma plc (LON:DDDD) Do Insiders Own?finance.yahoo.com - January 22 at 8:02 AM4D pharma hires new CFOproactiveinvestors.com - January 4 at 7:29 AM4D pharma appoints John Doyle as Chief Financial Officerfinance.yahoo.com - January 3 at 8:28 AM4D Pharma shares have rocketed and I’m tempted to buy nowfool.co.uk - November 10 at 1:09 PM4D pharma to Participate in Jefferies Virtual Next Generation IBD Therapeutics Summitfinance.yahoo.com - October 12 at 8:47 AM4d Pharma PLC : Half-year Reportmarkets.businessinsider.com - October 11 at 12:37 AM Get 4D pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for DDDD and its competitors with MarketBeat's FREE daily newsletter. Email Address World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea. Click here to find out what to do. DDDD Media Mentions By Week DDDD Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DDDD News Sentiment▼0.000.42▲Average Medical News Sentiment DDDD News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DDDD Articles This Week▼00▲DDDD Articles Average Week Get 4D pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for DDDD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: OKYO Pharma News C4X Discovery News Hemogenyx Pharmaceuticals News Arecor Therapeutics News Oncimmune News Oxford BioDynamics News Destiny Pharma News OptiBiotix Health News Ondine Biomedical News Sareum News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:DDDD) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
